H2i Ventures in the News: Mesosil and TalkToMedi
Here are a few recent updates from our H2i ventures as they continue to gain traction across the ecosystem:
Dentistry startup Mesosil gets FDA clearance
Mesosil has secured U.S. FDA 510(k) clearance for an antimicrobial biomaterial designed to prevent infection and extend the lifespan of dental restorations. Founded by dentistry alum Cameron Stewart, the technology targets the microscopic gap between a tooth and its filling, where bacteria can infiltrate and cause recurrent decay. Developed over more than a decade, Mesosil’s porous silica particles release antimicrobial agents gradually at the restoration interface, with early research showing improved infection control and bond strength. With $2.3 million raised and a growing team, the company is now focused on scaling production and building industry partnerships to support wider adoption of infection-resistant dental materials.
TalkToMedi improving patient access and raises pre-seed round
TalkToMedi has closed its pre-seed round led by Comma Capital to address one of healthcare’s most overlooked challenges: how patients access care. Built by a team of University of Toronto master’s students and engineers, the company has developed an AI agent that handles, triages, and responds to patient requests in real time, ensuring every interaction is captured, prioritized, and routed appropriately. The technology targets a common breakdown at clinic front desks, where demand spikes, phone lines jam, and urgent requests often go unanswered. Already deployed in real clinical environments, TalkToMedi has signed 50 clinics, processed over 40,000 patient calls, and achieved a 93% success rate in resolving inquiries without manual intervention. The company is now evolving its platform into a broader system for patient access, connecting fragmented administrative workflows into a more continuous and reliable care experience.